Last year, AstraZeneca PLC’s Truqap (capivasertib) became the first AKT inhibitor to gain approval, with the UK giant intending to build on this by expanding into other settings. Now it has admitted that the next step was more of a stumble, with the failure of the drug’s pivotal trial in triple-negative breast cancer (TNBC).
Key Takeaways
- The CAPItello-290 trial of Truqap in triple-negative breast cancer has failed, meaning the drug is stuck with a fairly narrow label for longer that AstraZeneca hoped.
CAPItello-290 found that Truqap plus paclitaxel showed no difference from paclitaxel and placebo in first-line locally advanced or metastatic TNBC...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?